title: Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemia.
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Renuka
authors.initials: R
authors.lastname: Palani
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Alistair
authors.initials: A
authors.lastname: Reid
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Letizia
authors.initials: L
authors.lastname: Foroni
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Simona
authors.initials: S
authors.lastname: Deplano
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D058070:Asymptomatic Diseases / Q000453:epidemiology; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000453:epidemiology*; D007093:Imidazoles / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000627:therapeutic use*; D012307:Risk Factors; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib; D013972:Thyrotropin; D013974:Thyroxine